KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $5.3 billion.

  • AbbVie's Cost of Revenue rose 2592.59% to $5.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 billion, marking a year-over-year decrease of 90.05%. This contributed to the annual value of $16.9 billion for FY2024, which is 1719.81% down from last year.
  • Per AbbVie's latest filing, its Cost of Revenue stood at $5.3 billion for Q3 2025, which was up 2592.59% from $4.3 billion recorded in Q2 2025.
  • Over the past 5 years, AbbVie's Cost of Revenue peaked at $6.5 billion during Q3 2023, and registered a low of $4.0 billion during Q1 2023.
  • Its 5-year average for Cost of Revenue is $4.5 billion, with a median of $4.2 billion in 2023.
  • In the last 5 years, AbbVie's Cost of Revenue skyrocketed by 11694.13% in 2021 and then plummeted by 3505.01% in 2024.
  • AbbVie's Cost of Revenue (Quarter) stood at $4.3 billion in 2021, then fell by 3.47% to $4.2 billion in 2022, then surged by 36.79% to $5.7 billion in 2023, then dropped by 22.93% to $4.4 billion in 2024, then rose by 20.66% to $5.3 billion in 2025.
  • Its Cost of Revenue was $5.3 billion in Q3 2025, compared to $4.3 billion in Q2 2025 and $4.0 billion in Q1 2025.